Company Profile

Paradigm Pharmaceuticals LLC (AKA: Paradigm Pharma Inc)
Profile last edited on: 7/16/2023      CAGE: 42VX4      UEI: LGX8KB5NT1J8

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2002
First Award
2002
Latest Award
2007
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2685 Patton Road
St. Paul, MN 55113
   (651) 628-0196
   N/A
   N/A
Location: Single
Congr. District: 04
County: Ramsey

Public Profile

Paradigm Pharmaceuticals, LLC is focused to to development of new and active pharmaceuticals for the prevention and treatment of viral infections and malignancies. Paradigm Pharmaceuticals is currently developing bench-to-bedside patent-applied technologies towards final product and approval stages in order to produce the highest quality pharmaceutical and consumer health care products in the world. Complete in house laboratory set-up with state-of-the-art equipment is established. Extensive research studies have been conducted and the most beneficial and extraordinary drug candidates have been tested in animal models to confirm efficacy, potency, and toxicity.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
20-24
Revenue Range
2M-2.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2007 2 NIH $681,590
Project Title: Vanadocenes as a New Class of Spermicidal Drugs
2005 1 NIH $100,000
Project Title: Formulation of dosage of the anti-HIV agent, DDE113
2005 1 NIH $100,000
Project Title: Stampidine: a Novel Broad-Spectrum Anti-HIV Microbicide
2005 2 NIH $850,002
Project Title: WHI-07: A Novel Dual-Function Microbicide
2005 2 NIH $850,000
Project Title: LFM-A13 for Prevention of Fatal Thromboembolism

Key People / Management

  Darin Dumez

  Sandeep Mahajan

  Peter Samuel

  Alexei Vassilev

  Taracad Venkatachalam

  Barbara Waurzyniak

Company News

There are no news available.